Millipore Sigma Vibrant Logo

SCC431 TB096 Human IDH1-Mutated Astrocytoma Cell Line

The TB096-2 cell line provides a strong in vitro model to further understand the role of IDH1 mutation in astrocytoma growth mediated by D-2HG conversion. This also provides opportunity to develop therapy solutions which may modulate D-2HG production and help understand the role of wild type IDH1 in conjunction with its mutated allele.

View Products on Sigmaaldrich.com
SCC431
≥1X10⁶ cells/vial  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
 
—
Request Pricing
—
Fulfillment and delivery delayed Fulfillment and delivery delayed
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

       

      Contact Customer Service

      Overview

      Replacement Information
      Description
      Catalogue NumberSCC431
      DescriptionTB096 Human IDH1-Mutated Astrocytoma Cell Line
      OverviewIn glioma cells, a specific point mutation occurs relatively often at the Arg132 location of the IDH1 protein (NADP+-dependent isocitrate dehydrogenase 1) resulting in a gain-of-function mutation that produces D-2-hydroxyglutarate (D-2HG), a prevalent metabolite attributed to carcinogenesis and tumor progression.1 The TB096-2 cell line provides a strong in vitro model to further understand the role of IDH1 mutation in astrocytoma growth mediated by D-2HG conversion. This also provides opportunity to develop therapy solutions which may modulate D-2HG production and help understand the role of wild type IDH1 in conjunction with its mutated allele.
      Background InformationAstrocytoma is a nervous system cancer that can be found in the brain or spinal cord. It begins in astrocytes, a type of glial cell which perform a variety of support functions for the nervous tissue such as nutrient transport, maintenance of ionic balance, and repair processes for brain and spinal cord injury. Astrocytoma are quite variable and can cause a solid range of symptoms depending on the location of the tumor. They can also vary in growth, ranging from rather slow-growing tumors to aggressive proliferative tumors.

      In glioma cells, a specific point mutation occurs relatively often at the Arg132 location of the IDH1 protein (NADP+-dependent isocitrate dehydrogenase 1) resulting in a gain-of-function mutation that produces D-2-hydroxyglutarate (D-2HG), a prevalent metabolite attributed to carcinogenesis and tumor progression.1 The TB096-2 cell line provides a strong in vitro model to further understand the role of IDH1 mutation in astrocytoma growth mediated by D-2HG conversion. This also provides opportunity to develop therapy solutions which may modulate D-2HG production and help understand the role of wild type IDH1 in conjunction with its mutated allele.

      Source
      TB096-2 was derived from a 26-year old male anaplastic astrocytoma WHO grade III patient treated at Duke in 2009.1 Tumors were obtained from the Brain Tumor Biorepository at Duke with written informed consent from patients and Institutional Review Board approval and analyzed previously for IDH mutation status.1

      References
      1. Cancer Res 2013; 73(2): 496-501.
      References
      Product Information
      Quality LevelMQ100
      Applications
      ApplicationThe TB096-2 cell line provides a strong in vitro model to further understand the role of IDH1 mutation in astrocytoma growth mediated by D-2HG conversion. This also provides opportunity to develop therapy solutions which may modulate D-2HG production and help understand the role of wild type IDH1 in conjunction with its mutated allele.
      Key Applications
      • Cell Culture
      Application NotesThis product is intended for sale and sold solely to academic institutions for internal academic research use per the terms of the “Academic Use Agreement” as detailed in the product documentation. For information regarding any other use, please contact licensing@emdmillipore.com.
      Biological Information
      Cell Line Type
      • Cancer Cells
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality Assurance• TB096-2 cells are verified to be of human origin and negative for mouse, rat, Chinese hamster, Golden Syrian hamster, and non-human primate interspecies contamination, as assessed by a Contamination Clear panel by Charles River Animal Diagnostic Services
      • Cells tested negative for infectious diseases against a Human Essential CLEAR panel by Charles River Animal Diagnostic Services.
      • Cells tested negative for mycoplasma.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsTB096-2 human IDH1-mutated astrocytoma cells should be stored in liquid nitrogen until use. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.
      Packaging Information
      Material Size≥1X10⁶ cells/vial
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      SCC431 04065267625317